祥生医疗（688358）1月21日主力资金净买入1259.61万元

Core Viewpoint - Xiangsheng Medical (688358) has shown a positive stock performance with a closing price of 38.64 yuan, up 5.54% as of January 21, 2026, indicating a favorable market sentiment towards the company [1]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the net profit excluding non-recurring items was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. - The gross profit margin stood at 59.82%, indicating a strong profitability despite the revenue decline [3]. Market Activity - On January 21, 2026, the net inflow of main funds was 12.60 million yuan, accounting for 8.9% of the total transaction amount, while retail investors experienced a net outflow of 15.15 million yuan, representing 10.71% of the total transaction amount [1]. - Over the past five days, the financing buy amounted to 16.43 million yuan, with a net repayment of 40,400 yuan, indicating a cautious approach from investors [2]. Institutional Ratings - In the last 90 days, three institutions have issued buy ratings for Xiangsheng Medical, reflecting a positive outlook from analysts [4].